Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Hauser

Showing results (41-50 of 266) with videos related to

Pageof 27
Sort By:
Clinical Parkinsonism & Related Disorders|January 21, 2022
Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapyRobert A Hauser, Santosh Goud, Andrea E Formella
Movement Disorders : Official Journal of the Movement Disorder Society|December 5, 2002
Clozapine withdrawal symptoms in a Parkinson's disease patientTheresa A Zesiewicz, Sujatha Borra, Robert A Hauser
Journal of Parkinson'S Disease|December 12, 2013
Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A)Robert A Hauser, L Arthur Hewitt, Stuart Isaacson
Neuropsychiatric Disease and Treatment|September 10, 2019
Impact of non-motor symptoms in Parkinson's disease: a PMDAlliance surveyNeal Hermanowicz, Sarah A Jones, Robert A Hauser
The American Journal of Medicine|January 4, 2014
An update on Parkinson's disease: improving patient outcomesDaniel Kremens, Robert A Hauser, E Ray Dorsey
Current Neurology and Neuroscience Reports|June 5, 2002
Management of essential tremorTheresa A Zesiewicz, Elmyra Encarnacion, Robert A Hauser
The International Journal of Neuroscience|February 15, 2012
The UPDRS-8: a brief clinical assessment scale for Parkinson's diseaseRobert A Hauser, Kelly E Lyons, Rajesh Pahwa
The Annals of Pharmacotherapy|September 20, 2007
Role of the pharmacist in the effective management of wearing-off in Parkinson's diseaseWilliam Simonson, Robert A Hauser, Anthony H V Schapira
Neurology|August 13, 2003
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PDRobert A Hauser, Jean P Hubble, Daniel D Truong, et al.
Parkinsonism & Related Disorders|December 28, 2020
Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)Robert A Hauser, Leonid Zeitlin, Stanley Fisher, et al.
Pageof 27

Showing results (41-50 of 266) with videos related to

Sort By:
Pageof 27
Clinical Parkinsonism & Related Disorders|January 21, 2022
Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapyRobert A Hauser, Santosh Goud, Andrea E Formella
Movement Disorders : Official Journal of the Movement Disorder Society|December 5, 2002
Clozapine withdrawal symptoms in a Parkinson's disease patientTheresa A Zesiewicz, Sujatha Borra, Robert A Hauser
Journal of Parkinson'S Disease|December 12, 2013
Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A)Robert A Hauser, L Arthur Hewitt, Stuart Isaacson
Neuropsychiatric Disease and Treatment|September 10, 2019
Impact of non-motor symptoms in Parkinson's disease: a PMDAlliance surveyNeal Hermanowicz, Sarah A Jones, Robert A Hauser
The American Journal of Medicine|January 4, 2014
An update on Parkinson's disease: improving patient outcomesDaniel Kremens, Robert A Hauser, E Ray Dorsey
Current Neurology and Neuroscience Reports|June 5, 2002
Management of essential tremorTheresa A Zesiewicz, Elmyra Encarnacion, Robert A Hauser
The International Journal of Neuroscience|February 15, 2012
The UPDRS-8: a brief clinical assessment scale for Parkinson's diseaseRobert A Hauser, Kelly E Lyons, Rajesh Pahwa
The Annals of Pharmacotherapy|September 20, 2007
Role of the pharmacist in the effective management of wearing-off in Parkinson's diseaseWilliam Simonson, Robert A Hauser, Anthony H V Schapira
Neurology|August 13, 2003
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PDRobert A Hauser, Jean P Hubble, Daniel D Truong, et al.
Parkinsonism & Related Disorders|December 28, 2020
Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)Robert A Hauser, Leonid Zeitlin, Stanley Fisher, et al.
Pageof 27